Aiming For Better, Cheaper ERT Drugs, Oxyrane Raises $26.5 Mil.
U.K biotech Oxyrane raises $26.5 million D round to advance enzyme replacement therapies and validate a technology platform that may lead to cheaper-to-produce and more effective ERTs
U.K biotech Oxyrane raises $26.5 million D round to advance enzyme replacement therapies and validate a technology platform that may lead to cheaper-to-produce and more effective ERTs